COMPANY PROFILE

InterVene

Explore full profile

Up and coming medical device start-up company

Mountain View, United StatesFounded 2011Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About InterVene

Intervene-med.com is dedicated to providing innovative and effective therapy for patients suffering from Chronic Venous Insufficiency (CVI) due to deep vein reflux (DVR). Operating in the medical technology sector, the company focuses on developing treatments that alleviate the painful and costly symptoms associated with CVI. Intervene-med.com primarily serves patients and healthcare providers in the United States, targeting a significant market need for advanced venous therapies. The business model revolves around the development and commercialization of proprietary medical devices and treatments, generating revenue through product sales and partnerships with healthcare institutions. By addressing a prevalent and underserved medical condition, Intervene-med.com aims to improve patient outcomes and reduce healthcare costs associated with CVI.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Mountain View, United States
Employees: 18
Open positions: None listed
Dealroom signal: 75.6/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning InterVene.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Oct 2024	$13M	$52M	RiverVest Venture Partners · Treo Ventures	↗
SERIES B✓Equity / VC	Jun 2019	$15M	$60M	Boston Scientific · RiverVest Venture Partners · Correlation Ventures · 3×5 Partners	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

InterVene website traffic

Latest recorded traffic for InterVene is 1.6K monthly website visits, down 23.8% over the last three months. InterVene's team grew 5.9% over the past year.

Latest monthly visits1.6K 3-month web change-23.8% 1-year team growth+5.9%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XBXellar BiosystemsAccelerating drug discovery through human-mimetic organ-on-a-chip technology, high-fidelity 3D disease models, and AI-powered spatiotemporal profiling.	Boston, United States	Operational	28	$85M	$118M
FBFOx BiosystemsFox biosystems produces fiber-optic biosensor instruments	Diepenbeek, Belgium	Operational
SBSatellite BioSpecializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering	Cambridge, United States	Operational
NSNimble ScienceNimble Science is a precision medicine company with a multi-omic data platform to transform GI Care from plate to bedside	Calgary, Canada	Operational
SYSyantraPrecision healthcare company that focuses on the commercialization of breast cancer detection blood tests	Calgary, Canada	Operational
GRGraymattersEEG-based self-neuromodulation therapy for mental health disorders	Haifa, Israel	Operational
ISInventia Life ScienceRevolutionising 3D cell biology	Sydney, Australia	Operational
RARapidAIThe worldwide leader in advanced imaging for stroke	Menlo Park, United States	Operational